{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:26:27Z","timestamp":1792614387962,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":1096,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jpainsymman.2017.07.033","type":"journal-article","created":{"date-parts":[[2017,7,23]],"date-time":"2017-07-23T01:32:31Z","timestamp":1500773551000},"page":"701-706.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer"],"prefix":"10.1016","volume":"54","author":[{"given":"Kathleen A.","family":"Griffith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Johantgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Renn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas S.","family":"Beutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Kanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Ambulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Cavaletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Bruna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Briani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas A.","family":"Argyriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralabos P.","family":"Kalofonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Yerges-Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan G.","family":"Dorsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2017.07.033_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/annonc\/mdg106","article-title":"Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer","volume":"14","author":"Kim","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ygyno.2005.08.020","article-title":"Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer","volume":"100","author":"Nicoletto","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"2 Pt 1","key":"10.1016\/j.jpainsymman.2017.07.033_bib3","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1078-0432.690.11.2","article-title":"Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial","volume":"11","author":"Scagliotti","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00280-009-0938-4","article-title":"Oxaliplatin, irinotecan, and fluorouracil\/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group","volume":"64","author":"Comella","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib5","first-page":"151","article-title":"Oxaliplatin\/5-FU\/LV in adjuvant colon cancer: results of the international randomized mosaic trial","volume":"22","author":"de Gramont","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib6","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"5 Suppl 15","key":"10.1016\/j.jpainsymman.2017.07.033_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/sonc.2002.35525","article-title":"Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures","volume":"29","author":"Gamelin","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib9","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib10","first-page":"1999","article-title":"A\u00a0systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration","volume":"227","author":"Beijers","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/jns.12097","article-title":"Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study","volume":"19","author":"Briani","year":"2014","journal-title":"J\u00a0Peripher Nerv Syst"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib12","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","article-title":"Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry","volume":"31","author":"Mols","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib13","first-page":"3307","article-title":"Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors","volume":"21","author":"Tofthagen","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/COC.0b013e318246b50d","article-title":"Predicting acute and persistent neuropathy associated with oxaliplatin","volume":"36","author":"Alejandro","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jnnp-2013-305334","article-title":"Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients","volume":"85","author":"Velasco","year":"2014","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib16","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14740338.2011.543417","article-title":"Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence","volume":"10","author":"Balayssac","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.expneurol.2011.02.019","article-title":"Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline","volume":"229","author":"Boyette-Davis","year":"2011","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/cncr.27732","article-title":"Clinical pattern and associations of oxaliplatin acute neurotoxicity","volume":"119","author":"Argyriou","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000362668","article-title":"Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer","volume":"87","author":"Altaf","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer\u2014a GERCOR study","volume":"24","author":"Tournigand","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib22","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings","volume":"24","author":"Cavaletti","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib23","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/cncr.28234","article-title":"Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study","volume":"119","author":"Argyriou","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib24","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.53.8.1660","article-title":"Total neuropathy score: validation and reliability study","volume":"53","author":"Cornblath","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","article-title":"The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale","volume":"12","author":"Cavaletti","year":"2007","journal-title":"J\u00a0Peripher Nerv Syst"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/NCC.0b013e3181c989a3","article-title":"The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums","volume":"33","author":"Smith","year":"2010","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib27","unstructured":"Muth\u00e9n LK, Muth\u00e9n BO. Mplus user's guide. 7th ed. Los Angeles: Muthen & Muthen"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/10705510701575396","article-title":"Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo Simulation study","volume":"14","author":"Nylund","year":"2007","journal-title":"Struct Equ Model A Multidiscip J"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jns.12140","article-title":"Rasch-transformed Total Neuropathy Score clinical version (RT-TNSc\u00a9) in patients with chemotherapy-induced peripheral neuropathy","volume":"20","author":"Binda","year":"2015","journal-title":"J\u00a0Peripher Nerv Syst"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib30","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/S0959-8049(15)30023-X","article-title":"Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel","volume":"51","author":"Ventzel","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib31","first-page":"1161","article-title":"Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations","volume":"225","author":"Griffith","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib32","first-page":"647","article-title":"Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?","volume":"13","author":"Argyriou","year":"2005","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib33","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","article-title":"Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance)","volume":"33","author":"Pachman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000442527","article-title":"Diabetes and body mass index are associated with neuropathy and prognosis in colon cancer patients treated with capecitabine and oxaliplatin adjuvant chemotherapy","volume":"90","author":"Ottaiano","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib35","first-page":"1873","article-title":"Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy","volume":"25","author":"Cox-Martin","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib36","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1212\/01.wnl.0000249344.99671.d4","article-title":"Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy","volume":"67","author":"Argyriou","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","article-title":"Chemotherapy-induced peripheral neurotoxicity (CIPN): an update","volume":"82","author":"Argyriou","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/annonc\/mdt568","article-title":"Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy","volume":"25","author":"Streckmann","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib39","first-page":"1020","article-title":"New practical approaches to chemotherapy-induced neuropathic pain: prevention, assessment, and treatment","volume":"30","author":"Majithia","year":"2016","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jpainsymman.2017.07.033_bib40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejon.2015.10.007","article-title":"Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life","volume":"21","author":"Hwang","year":"2015","journal-title":"Eur J Oncol Nurs"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088539241730297X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088539241730297X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:20:29Z","timestamp":1760131229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088539241730297X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S088539241730297X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2017.07.033","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2017.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine.","name":"copyright","label":"Copyright"}]}}